4.6 Article

Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection

Journal

JOURNAL OF VIROLOGY
Volume 76, Issue 24, Pages 12584-12595

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/JVI.76.24.12584-12595.2002

Keywords

-

Categories

Funding

  1. NIAID NIH HHS [R01 AI031563, T32 AI007387, AI 31563, T332 AI 07387-12] Funding Source: Medline
  2. NIDDK NIH HHS [DK 57857, R01 DK057857] Funding Source: Medline

Ask authors/readers for more resources

Vigorous virus-specific CD4(+) T-helper-cell responses are associated with successful control of hepatitis C virus (HCV) and other human viral infections, but the breadth and specificity of responses associated with viral containment have not been defined. To address this we evaluated the HCV-specific CD4(+) T-helper-cell response in HCV antibody-positive persons who lack detectable plasma viremia, and compared this response to that in persons with chronic HCV infection. Peripheral blood mononuclear cells were stimulated with HCV proteins, followed by measurement of HCV-specific CD4'-T-cell responses to a comprehensive set of overlapping HCV peptides by intracellular gamma interferon production. In three persons with resolved HCV infection studied in detail, 13 to 14 epitopes were targeted, but none was recognized by all three. The 37 defined epitopes were predominantly distributed among the HCV proteins core, NS3, NS4, and NS5. In an expanded analysis of responses to these proteins in persons with resolved infection, an average of 10 epitopes was targeted, whereas in persons with chronic viremia never was more than one epitope targeted (P < 0.001). This comprehensive analysis of the breadth and specificity of HCV-specific T-helper-cell responses indicates that up to 14 viral epitopes can be simultaneously targeted by circulating virus-specific CD4(+) T helper cells in a controlled human viral infection. Moreover, these data provide important parameters for evaluation of candidate HCV vaccines, and provide rationale for immunotherapy in chronic HCV infection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available